Lilly further boosts cancer pipeline with $8bn Loxo acquisitionIn the second big M&A deal of the year following BMS’s acquisition of Celgene, Eli Lilly has announced Share XLilly further boosts cancer pipeline with $8bn Loxo acquisitionhttps://pharmaphorum.com/news/lilly-further-boosts-cancer-pipeline-with-8bn-loxo-acquisition/
Bayer/Loxo drug approved in cancers with certain mutationThe FDA has approved Bayer and Loxo’s Vitrakvi (larotrectinib) for adults and children whose cancers have a specific Share XBayer/Loxo drug approved in cancers with certain mutationhttps://pharmaphorum.com/news/bayer-loxo-drug-approved-in-cancers-with-certain-mutation/
ASCO 2018 – Tuesday 5th June: Tesaro developing checkpoint comboBreast cancer has been one area where checkpoint inhibitors have not yet gained traction – but that might Share XASCO 2018 – Tuesday 5th June: Tesaro developing checkpoint combohttps://pharmaphorum.com/views-and-analysis/asco-2018-tesaro-checkpoint-combo/
